Keywords:
Performed at one institution, Observational, Prospective, Cancer, Diagnostic procedure, MR, Cardiovascular system, Cardiac
Authors:
N. A. Atia1, L. Lehmann2, H. Goldschmidt2, F. André2, J. Salatzki2, M. G. friedrich3, H. Katus2, J. Riffel2; 1Tanta/EG, 2Heidelberg/DE, 3Montreal/CA
DOI:
10.26044/ecr2020/C-03068
Methods and materials
Patients (see Table 1) diagnosed with multiple myeloma and scheduled to undergo treatment with Carfilzomib have been recruited and performed three CMR examinations using clinical 1.5T and 3T MRI systems (Philips Ingenia_CX and Ingenia, Best, Netherlands). Scans were performed before onset of therapy (baseline) as well as 3-5 days and 3 months thereafter.
The CMR parameters included standard morphological and functional parameters for left and right ventricles (LV/RV) i.e. ejection fraction (EF), enddiastolic volume/body surface area (EDV/BSA), endsystolic volume/BSA (ESV/BSA), mitral and tricuspid annular plane systolic excursion (MAPSE, TAPSE) as well as tissue characterization parameters (LV global T1 & T2 Mapping) (see Figure 2) and deformation parameters (LV & RV global longitudinal and circumferential myocardial strain (GLS) and (GCS)) from fSENC data (Myocardial Solutions, Morrisville, US).
All data were compared between baseline, 1st and 2nd follow up using paired t-test as the data were normally distributed.